Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Hemp-derived products debate stalls after agencies warn bill could undermine existing litigation and public-health protections
Summary
Sen. Joshua Bryant’s proposal to regulate hemp-derived cannabinoid products prompted expert testimony and warnings from the Attorney General’s office and public-health officials that the bill’s current text could interfere with ongoing litigation and weaken enforcement against synthetic cannabinoids.
Senate testimony on a bill introduced by Sen. Joshua Bryant (Senate District 32) would have created a regulatory framework for hemp-derived products containing intoxicating cannabinoids, including childproof packaging, manufacturing and testing requirements, age‑restricted sales (21+), and a contingency-based effective date tied to federal litigation over Arkansas’s 2023 ban (Act 629).
Bryant said the intent is to protect children by restricting marketing and requiring testing from accredited laboratories (ISO/IEC 17025 or equivalent) and to remove synthetic cannabinoids from the market while preserving…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
